The capacity of interferon-gamma to regulate the generation and release of leukotriene B4 (LTB4) from human alveolar macrophages of normal nonsmoking individuals was evaluated. When alveolar macrophages were incubated for 60 min with heat aggregated IgG (HAIgG), they generated and released 5.7 +/-1.7 ng of LT B4 per 10(6) cells compared to 1.9 +/-0.4 ng from cells incubated with buffer alone, P = 0.02. When alveolar macrophages were preincubated with interferon-gamma for 24 h before activation for 60 min with heat-aggregated IgG, the soluble IgG aggregates became a significantly more effective stimulus for LTB4 release, 17.0 +/-3.9 ng/10(6) cells, P = 0.001, compared to cells incubated in the absence of interferon-gamma and challenged with HAIgG. Interferongamma did not alter the response to A23187. This effect of interferon-gamma was both time and dose dependent; it also was specific since neither interferon-alpha nor interferon-beta had a regulatory effect on the release of LTB4 from cells in response to challenge with HAIgG. Preincubation of the alveolar macrophages with interferon-gamma augmented the density of IgG1 receptors by 81.5 +/-17.3%; neither interferon-alpha nor interferon-beta effected this parameter. Furthermore, monomeric IgG1 blocked HAIgG induced LTB4 release from alveolar macrophages primed with interferon-gamma. Therefore, at least one of the mechanisms by which interferon-gamma primes alveolar macrophages for the production and release of LTB4 […] phages primed with interferon-gamma. Therefore, at least one of the mechanisms by which interferon-gamma primes alveolar macrophages for the production and release of LTB4 in response to stimulation by aggregates of IgG is that of increasing the number of receptors for this stimulus.
Introduction
Alveolar macrophages (AM)' reside on the epithelial surfaces of the lower respiratory tract and have been implicated as being central to the evolution of a variety of inflammatory events in the lung (1, 2) . In brane origin, which are synthesized de novo after cell activation (1) (2) (3) (4) . For these cells, only zymosan and the calcium ionophore A23 187 are known to activate both phospholipase A2 to cleave arachidonic acid from some pools of membrane phospholipids and also the calcium-dependent oxidative metabolism of arachidonic acid by the 5-lipoxygenase to leukotriene A4. Leukotriene A4 then is catalytically hydrolyzed to leukotriene B4 (LTB4) (5-7). As a proinflammatory mediator, LTB4 is of particular interest because of its numerous effects on a variety of leukocytes. These effects include potent chemokinetic and chemotactic activity for human neutrophils (8-1 1), eosinophils (10) (11) (12) (13) , and monocytes (8, 14) in vitro, induction of human neutrophil aggregation (9) , and stimulation of rabbit and human neutrophil lysosomal enzyme release (15) . In addition, LTB4 exerts potent immunoregulatory effects on human peripheral blood lymphocytes with the net effect being immunosuppression (16) (17) (18) . In order to extend the relevance of these observations to the spectrum of human inflammatory lung diseases, we used a receptor-dependent soluble activator, heat aggregated IgG (HAIgG). In addition, we assessed the effect of an immune response regulator, human interferon-gamma (IF-'y), on human AM generation and release of LTB4.
Human IF-'y is a 20,000 mol wt glycoprotein produced by lymphocytes (19, 20) and human AM (21) in response to a variety of stimuli (22) . Many (23) , and recently, receptors for IF-'y have been found on human peripheral blood monocytes (24) . Some ofthe effects ofIF-'y on macrophages or monocytes include augmenting expression of MHC class 2 antigens and antigen presentation to lymphocytes (25) , enhancing cytotoxicity for tumor cells (26) and intracellular parasites (27) , and augmenting the density of IgG Fc receptors (IgGFcR) (28) . Based on these observations, we hypothesized that IF--y might increase LTB4 release from human AM when they were challenged with the immunologically relevant stimulus, HAIgG.
Methods
Preparation ofAM cultures. Human AM from nonsmoking normal volunteers were retrieved by bronchoalveolar lavage (BAL) (29) .
Briefly, all subjects had normal medical histories, chest radiographs, spirometry, and complete blood counts, and none admitted to any illness including a respiratory tract infection for which any medication, including nonsteroidal antinflammatory agents, was required in the 4-wk period before participation. After topical 4% lidocaine anesthesia was applied to the oropharynx, BAL was performed through a fiberoptic bronchoscope, wedged in a segmental bronchus, by instilling sterile normal saline in 50-ml aliquots and gently aspirating after each instillate. A maximum of 300 ml was instilled into each lung of an individual volunteer. BAL aliquots were pooled, filtered through a single layer of gauze, and centrifuged at 500 g for 5-10 min at 240C.
The cells were washed twice in Ca2l and Mg2e free HBSS (Grand Island Biological Co., Grand Island, NY) and resuspended in McCoy's 5a medium (Grand Island) containing 5% heat-inactivated fetal bovine serum (HIFBS) (KC Biological Co., Lenexa, KS) supplemented with 100 U/ml penicillin, and 100 tg/ml streptomycin. Total cells were counted on a hemocytometer, viability was assessed by cellular exclusion of trypan blue, and differential cell counts were made on Wrightstained cytocentrifuge preparations. Lavage cells prepared in this way averaged (mean±SEM) 85.1±1.0% AM, 13.4±1.0% lymphocytes, 1.1±0.1% polymorphonuclear cells, 0.7±0.2% mast-basophiloid cells, and 0.5±0.1% eosinophils, n = 85. Macrophage viability averaged 88.7±0.6%. Platelet contamination, estimated from the small number of red blood cells, 9.8±1.7% of total cells recovered, present in the lavage fluid due to trauma of the airway epithelium by the tip of the bronchoscope, never exceeded one platelet per two nucleated cells. For the cell cultures used in the assessment of leukotriene release, lavage cells were adjusted to 2 X 106 cells per ml and placed into sterile 7-ml Teflon chambers (Scientific Specialties, Randallstown, MD).
Preparation ofHAIgG. The gamma-globulin fraction from 30-50 ml offresh human serum was obtained by precipitation with one-third saturated ammonium sulfate, extensively dialyzed against 0.05 M Tris-HCl, pH 8.0, and was partially purified by ion exchange column chromatography on diethylaminoethyl cellulose (DEAE 52, Whatman; H. Reeve Angel, Inc., Clifton, NJ). This was followed by dialysis against PBS 0.1 M, pH 7.2, and 0.1% sodium azide, with subsequent filtration on Sephadex G-200-gel bed volume 150 ml-(Pharmacia Fine Chemicals, Piscataway, NJ) that had been previously calibrated with the following standards: blue dextran, 1 I s-IgA (kindly provided by Dr. H. Y. Reynolds, Yale University School of Medicine), IgG, and albumin. The IgG containing eluates from each column were detected by absorbance at 280 nm and their known elution times for these columns. After the initial isolation of IgG from the G-200 column, the IgG was concentrated by positive pressure ultrafiltration through a UMOI0 membrane (Amicon Corp., Lexington, MA). HAIgG was prepared by incubating the IgG (10 mg/ml) at 63°C until slight opalesence appeared and then centrifuging at 3,000 rpm for 10 min (30) . The supernatant then was refiltered over the Sephadex G-200 column and the void volume containing the IgG aggregates was retained, concentrated by positive pressure ultrafiltration, and dialyzed into Dulbecco's PBS, pH 7.2 (Gibco Laboratories, Grand Island, NY). The presence and purity of IgG aggregates was verified by immunoprecipitation diffusion-in-gel analysis using specific rabbit anti-human albumin, transferrin, whole serum, and immunoglobulin G and A antisera (Calbiochem-Behring Corp., San Diego, CA) and calculated to be > 99% pure. After sterilization by filtration through a 0.2-,gm membrane, the amount of HAIgG was quantified by the method of Lowry (31) using bovine gamma globulin to generate the standard curve (Bio-Rad Laboratories, Richmond, CA). The presence of endotoxin in the HAIgG preparations and cell culture supernatants was quantitated using a Limulus assay sensitive to 1.0 ng/ml, as described (32 , the cell cultures were incubated under identical conditions at a single interferon concentration, 1,000 U/ml. Stimulation ofhuman AM. Bronchoalveolar lavage cells, after incubation with IF--y as described above, were incubated for 30 min at 370C, in an atmosphere of air and 5% CO2 and with media containing 2 MM A23187 (Calbiochem-Behring Corp.), which was dissolved in dimethylsulfoxide and diluted to 0.1% (vol/vol) in the cell cultures. Then, the cells were centrifuged at 500 g for 5 min and the supernatants were harvested and stored at -70'C until assayed by RIA for LTB4. Preliminary observations in our laboratory indicated that storage of macrophage supernatants under these conditions for as long as one year did not adversely affect the recovery of immunoreactive LTB4. When reverse-phase high performance liquid chromatography (RP-HPLC) was to be performed for resolution of LTB4, the supernatants were mixed with 4 vol of ethanol before being stored at -70'C. Just before chromatography, the samples were warmed to 40C and centrifuged at 2,000 g for 10 min at 40C to remove precipitated proteins. The supernatants were evaporated to dryness under reduced pressure in a Speed Vac Concentrator (Savant Products, Hicksville, NY) and resuspended in either RIA buffer for LTB4 determination or mobile phase solvent for RP-HPLC.
Some of the selected cell cultures, which were to be stimulated by HAIgG, were first treated with IF-,y, then washed and resuspended in HBSS and challenged with 25-50 ug/ml of HAIgG for 1 h at 370C, under 5% CO2. The cell cultures were processed for LTB4 by RIA goat anti-rabbit IgG (Bio-Rad Laboratories), and the incubation was continued for 18-20 h. The immune precipitates were sedimented at 12,000 g for 3 min and 800 Mul of the solution phase added to 10 ml of scintillation cocktail, and assessed for radioactivity in a liquid scintillation counter. There was no difference in standard curves run in the presence or absence of 1,000 U/ml of IF-'y. The minimum quantities of LTB4 detectable with this assay were 1.5 ng/ml. The second and more sensitive RIA (minimum detectable levels of 0.5 ng/ml) employed dextran-coated charcoal to separate antibody-bound LTB4 from unbound LTB4 (34) . Results from the two assays were compared to each other and to results obtained with RP-HPLC on aliquots ofcell supernatants. LTC4 was quantitated using a charcoal RIA which was able to detect a minimum of 0.5 ng/ml and was purchased from New England Nuclear. Quantities ofleukotriene in nanograms per milliliter were adjusted to nanograms/106 viable alveolar macrophages.
RP-HPLC. RP (36) . The performance of the two chromatography systems was essentially equivalent. Synthetic LTC4, LTD4, and LTE4 standards were provided by J. Rokach.
IgG rosette assay. Rosette assays were performed as described by Spiegelberg and co-workers (37). Briefly, ox erythrocytes (Colorado Serum, Denver, CO) were washed thoroughly in PBS and were sensitized with that subagglutinating concentration of rabbit IgG anti-ox red blood cell antibody (Cappel Laboratories, Cochranville, PA) which resulted in rosette formation of -40% offresh human alveolar macrophages. The rosette assays were performed by mixing 50 Ad of 1% ox erythrocytes, suspended in McCoy's 5a medium supplemented with 5% HIFCS, with 50 AI of lavage cells (5 X 106/ml) suspended in the same medium. The mixture was centrifuged at 200 g for 1 min and incubated on ice for 1 h. The cells then were agitated to gently resuspend them, and the number ofcells bearing three or more erythrocytes counted as IgG receptor positive. Assays performed using ox erythrocytes not coated with anti-ox cell antibody served as controls.
Purification and iodination ofIgG, monomer. IgG, monomer was prepared from the serum of a patient with monoclonal IgG, myeloma as summarized previously (38) . Briefly, serum gamma globulin was twice precipitated, first with the addition of dry weight ammonium sulfate to 30% concentration, and then the supernatant was adjusted to 50% concentration. The precipitates were dialyzed extensively against 0.01 M PBS/azide, pH 7.4, to remove ammonium sulfate and then against 0.02 M Tris-HCI in preparation for anion exchange column chromatography on DEAE-52. The IgG was eluted with a logarithmic gradient of 0.5 M NaCl in 0.02 M Tris-HCl. The IgG-rich fractions were gel filtered on Sephadex G-200. The fraction that eluted after an I IS-IgA standard was collected, concentrated, and iodinated with 125I (New England Nuclear) by the lactoperoxidase-glucose oxidase method (Enzymobeads; Bio-Rad). Briefly, 15 AI of I 1.0 mg/ml monomeric IgG, were added to 50 Ml of preswollen enzymobeads and 50 M1 of 0.2 M phosphate buffer, pH 7.2. After adding 1.0 mCi of '251, the reaction was initiated by adding 50 Ml of 1% B-D-glucose, and continued for 30 min at room temperature; the reaction was terminated by the addition of 50 M of 1% sodium azide. Iodinated IgG, was separated from unbound 125I by filtration over a Bio-Gel P-6DG (Bio-Rad) column. In all instances over 95% of the radioactivity was precipitable with 20% TCA. Ultracentrifugation ofa trace quantity ofthe iodinated IgG, on a 10-40% sucrose density gradient at 35,000 g for 18 h verified that the IgG, was monomeric and that the iodination procedure did not result in aggregation ofthe ligand. IgG, concentrations in the final preparations were determined by the method of Lowry (31) using an IgG standard (Bio-Rad). The mean±SEM specific activity was 1.43±0.37 MCi/Mg IgG1. '25I-IgG, was stored at 4°C and was used within 2 wk of preparation.
Binding studies of monomeric '25I-IgG, to AM. The binding of radioligand to alveolar macrophages was carried out in PBS (Dulbecco's; Gibco) pH 7.2, supplemented with 0.1% sodium azide, 0.1% EDTA, and 0.1% human serum albumin (39 To determine if these differences were due to variances in measurements by the two RIAs, we compared LTB4 concentrations in aliquots of 10 additional supernatants from cells stimulated with A23187, HAIgG, or buffer alone. We found no significant difference (P < 0.6) in the amounts of LTB4 determined with either RIA. The correlation coefficient between values obtained with the two assays was excellent, r = 0.967, P < 0.001. More importantly, LTB4 concentrations quantitated using the more sensitive dextran-charcoal RIA were within a mean of 33.0±6.3% of the determinations made with the double-antibody RIA. The differences in LTB4 determined with each RIA were similar at both high and low LTB4 ranges. When the results of all supernatants from both groups of subjects were combined without regard to the RIA used, AM challenged with HAIgG generated and released 5.7±1.7 ng/ 106 viable AM compared with cells incubated with buffer alone, which released 1.9±0.4 ng/106 viable AM, P = 0.02, (n = 27). Thus, HAIgG is an effective stimulus for the release of LTB4 by AM from some normal nonsmoking subjects.
Release ofLTB4from human AM preincubated with IF--y. The time curve for release of immunoreactive LTB4 from AM after incubation with 1,000 U/ml of IF-ey for 24 h at 370C and subsequent to challenge with HAIgG was assessed using the double-antibody RIA (Fig. 2) . When macrophage cell cultures were challenged at 370C with 25-50 ug/ml ofHAIgG for times varying between 2.5 min and 3 h, net release of immunoreactive LTB4 occurred in some instances at the earliest time point measured, 2.5 min. Maximal release of LTB4 varied between experiments, occurring between 2.5 min and 1 h after incubation with HAIgG. Therefore, a 1-h incubation period was utilized for all subsequent experiments involving HAIgG challenge. Detection of immunoreactive LTB4 decreased progressively in all experiments by 2 h. The decline in the quantities of LTB4 detected over time in the macrophage supernatants was not due to absorption of leukotriene onto the Teflon chamber because, when 5,000 cpm of [3H]LTB4 were added to 1 ml of macrophage culture medium containing either A23187 or HAIgG and the mixtures were incubated at 37°C for 90 min, HAIgG dose-response curves were performed using concentrations ranging from 2.5 ng to 250 ,g/ml on AM preincubated with 1,000 U/ml of IF-y (Table I ). The HAIgG dose-response of LTB4 release was progressive up to a concentration of 25 gg/ml and remained constant at the highest concentration, 250 ,g/ml.
In paired experiments, the effects of incubating alveolar macrophages without IF-'y or with 10 U/ml, 100 U/ml, and 1,000 U/ml of IF-,y for either 1 h or 24 h before stimulation with either A23 187 or HAIgG were assessed using the double- 3 A. In 9 of the 12 experiments the increase in LTB4 release from primed AM exceeded 100%. In an additional 15 experiments where AM were cultured either without IF-'y or with 1,000 U/ml of IF-'y, and LTB4 was assayed with the dextrancoated charcoal RIA, HAIgG induced the release of 8.9±2.8 and 21.6±6.5 ng of LTB4/106 viable AM, respectively (data not shown, P = 0.01). In these later experiments concentrations of LTB4 rose by > 100% in 8 of the 15 experiments. The ability of IF-y to augment HAIgG induced LTB4 release was not due to a stimulus-independent increase in the overall capacity of the cell to generate LTB4, because A23 187-induced release of LTB4 from unprimed AM, 86.9±15.0 ng/106 viable AM, did not change statistically after macrophages were incubated with IF-'y under similar conditions, 60.9±11.9 ng/106 viable AM (n = 12) (Fig. 3 B) .
Because stimulation of polymorphonuclear leukocytes with unopsonized zymosan results in the cellular retention of -80% of the generated LTB4 (35), we assessed the cellular and extracellular distribution of LTB4 generated from macrophages incubated with 1,000 U/ml of IF-'y for 24 h and subsequently challenged with HAIgG or A23187. In two experiments A23187 stimulated macrophages released into the su- Reverse-phase HPLC. RP-HPLC was utilized to verify that the immunoreactive material in macrophage supernatants was LTB4. For these experiments aliquots of supernatants from noninterferon and IF-e (1,000 U/ml)-treated cell cultures which had been challenged with HAIgG, n = 3, were pooled, extracted with methanol, and subjected to RP-HPLC (Fig. 4) . Chromatographic peaks which coeluted with synthetic LTB4 standard were observed in both aliquots. As HAIgG (Fig. 5) . As assessed by the double-antibody RIA, macrophages challenged with HAIgG after culture with IF-a released 2.2±0.6 ng of immunoreactive LTB4/ 106 viable AM and after culture with IF-(3, 3.2±0.8 ng/106 viable AM, which was not significantly different from that released from cells challenged with HAIgG after culture in the absence of either interferon, 2.8±0.8 ng/106 viable AM, n = 7. In contrast, in these same experiments macrophages incubated with IF-y and challenged with HAIgG released 10.2±2.6 ng/106 viable AM, which was significantly different from that released without interferon, 2.9±0.8 ng/106 viable AM, (P = 0.04), n = 7.
Effect ofinterferons on alveolar macrophage IgG receptors.
In three experiments we assessed the effect of IF-y on the percentage of alveolar macrophages forming rosettes with IgG-coated ox red blood cells. After incubation in the absence of IF-ey for 24 h at 370C, 39 .3±10.6% of macrophages were IgGFcR+, whereas incubation of macrophages with 1,000 U/ml of IF-y for 24 h resulted in a statistically significant increase in the percent of IgGFcR+ macrophages to 61.3±8.3%, P < 0.04. These data suggested that either the number or the density of IgGFcR receptors on the cell surface increased or that the binding affinity of receptor for ligand increased in response to incubation with IF-Sy.
These possibilities were explored further using Scatchard (Table II) . Similarly, no change in the Ka was observed for cells cultured with either IF-a or IF-,8 (Table II) 
Discussion
The results ofthis study demonstrate that soluble aggregates of human IgG are an effective stimulus for LTB4 release from normal human AM, and that release due to HAIgG is enhanced significantly when these cells are preincubated with (Fig. 1) . This is much higher than the amounts reported to be released from unstimulated peripheral blood monocytes (43), and suggests that in the "resting state," AM are in a higher state of activation with respect to LTB4 production than are peripheral blood monocytes, a conclusion supported by others (49). Assuming that the differences are not due to differences in the methods ofcell harvesting, this would not be surprising in view ofthe fact that alveolar macrophages are constantly in contact with gasses, fumes, and particulate matter present in the atmosphere and inhaled each day.
Release of LTB4 by HAIgG from IF-y primed AM was generally rapid but the total immunoreactive LTB4 had decreased by 2 h in the supernatants of AM from all of five subjects (Fig. 2) . This was not due to a decrease in cell viability, (57) . These differences may reflect any of a number of variables between the studies, including those of species, culture conditions, and the nature of the agonists employed.
The findings of our study have potential relevance to host lung defense mechanisms. One classification divides these mechanisms into two broad groups: surveillance mechanisms and augmenting mechanisms (1) . Our 
